Skip to main content
Clinical Trials/NCT02567968
NCT02567968CompletedPhase 4

A Randomized, Double-Blinded, Placebo-Controlled Study to Determine if Caffeine Citrate Accelerates Emergence From Anesthesia

University of Chicago1 site in 1 country8 target enrollmentStarted: August 2016Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
8
Locations
1
Primary Endpoint
Waking Time - Re-establishment of the Gag Reflex.

Study Overview

Brief Summary

At present clinicians have no way to reverse anesthesia. Patients wake when their bodies clear the anesthetic. Most people wake quickly, but some do not. All patients have memory and other cognitive problems after waking from anesthesia. In studies on animals, the investigators observed that caffeine caused rats and mice to wake much more rapidly from anesthesia. This was true for all the animals tested. The investigators would like to see if this holds true in humans. Will caffeine accelerate waking from anesthesia? Will it reverse the cognitive deficits associated with anesthesia, after waking?

The investigators carried out a modest trial with 8 test subjects. Each volunteer was anesthetized twice. Each volunteer was anesthetized one time and received an infusion of saline (placebo control), without the aid of any other drugs and the other time the volunteer received an infusion of a relatively low dose of caffeine. The order of saline versus caffeine was randomized and the study was done in a double blind manner. We observed that emergence from anesthesia was significantly accelerated by the caffeine infusion. No adverse events were observed.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Prevention
Masking
Double (Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
25 Years to 40 Years (Adult)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Normal healthy subject without systematic diseases or conditions.
  • Metabolic Equivalents of Functional Capacity >=
  • Low risk for Obstructive Sleep Apnea (OSA) based on the screening test (STOP-bang score established by American Society of Sleep Apnea): Yes to > 3 items- high risk of OSA
  • No History of Arrhythmia (Baseline EKG will be obtained during the history and physical session), seizure, liver and kidney diseases.
  • BMI < 30 kg/m
  • No history of prior difficulty with anesthesia.
  • No personal or family history of malignant hyperthermia.
  • No history of any mental illness.
  • No history of drugs or alcohol abuse (urine drug screens required).
  • Subjects capable of giving consent.
  • Living less than 30 miles away from University of Chicago.
  • No history of seizure disorders.
  • No history of head trauma.

Exclusion Criteria

  • Age <25 or >
  • ASA physical status > 1 (normal healthy subject without systematic diseases or conditions)
  • Metabolic Equivalents of Functional Capacity (METs) <
  • High risks for Obstructive Sleep Apnea (OSA) based on the screening test (STOP-bang score established by American Society of Sleep Apnea): Yes to > 3 items- high risk of OSA
  • History Arrhythmia (Baseline EKG will be obtained during the history and physical session), seizure, liver and kidney diseases
  • BMI>30 kg/m
  • Prior difficulty with anesthesia.
  • Personal or family history of malignant hyperthermia.
  • History of any mental illness.
  • History of drugs or alcohol abuse (urine drug screens required)
  • Subjects capable of giving consent
  • Living more than 30 miles away from University of Chicago.
  • History of seizure disorders.
  • History of head trauma.

Arms & Interventions

Placebo

Placebo Comparator

Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.

Intervention: Placebo Control (Drug)

Caffeine

Active Comparator

Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.

Intervention: Caffeine (Drug)

Outcomes

Primary Outcomes

Waking Time - Re-establishment of the Gag Reflex.

Time Frame: followed from the end of anesthesia to gag reflex, up to 2 hours

The goal of the study is to determine whether caffeine speeds emergence from anesthesia. The time between terminating delivery of anesthetic and the subject starting to gag was measured. Anesthesia suppresses the gag reflex. Immediately after anesthetizing the test subject, a laryngeal mask airway (LMA) device was inserted into the test subject airway. After anesthesia was terminated and emergence from anesthesia was taking place, the gag reflex was re-established, and the LMA produced a "gag response" in all test subjects. This objective and unequivocal measurement constituted the "emergence" time for each subject. The "emergence" time was defined as the time between terminating the anesthesia and the test subject starting to gag.

Secondary Outcomes

  • Cognitive Test1 - Visual Analog Scale --- Feel Bad(Test was given at 15, 30, 45, 60, 75, 90, 105 and 120 minutes after terminating anesthesia.)
  • Minute Ventilation(Continuous monitoring from time lma inserted until subject started to gag and it was removed, up to 2 hours post-anesthesia.)
  • Cognitive Test3 - Divided Attention Task(Test was given at 15, 30, 45, 60 minutes after terminating anesthesia.)
  • Bispectral Index(Continuous monitoring from start of anesthesia until discharge of test subject, up to 2 hours post-anesthesia.)
  • Cognitive Test1 - Visual Analog Scale --- Feel Good(Test was given at 15, 30, 45, 60, 75, 90, 105 and 120 minutes after terminating anesthesia.)
  • Cognitive Test2 - Sternberg Test of Memory(Test was given at 15, 30, 45, 60 minutes after terminating anesthesia.)
  • Mean Arterial Blood Pressure(Continuous monitoring from start of anesthesia until discharge of test subject, up to 2 hours post-anesthesia.)
  • Heart Rate(Continuous monitoring from start of anesthesia until discharge of test subject, up to 2 hours post-anesthesia.)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 4
A Study to Determine if Caffeine Accelerates Emergence From Propofol AnesthesiaAnesthesia
NCT03360903University of Chicago8
Active, not recruiting
Phase 1
A Study Evaluating Xilonix™ in Symptomatic Colorectal Cancer Patients Refractory To Standard TherapySymptomatic Colorectal CancerMedDRA version: 17.1Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-000550-12-HUXBiotech Germany GmbH276
Active, not recruiting
Not Applicable
A Study Evaluating Xilonix™ in Symptomatic Colorectal Cancer Patients Refractory To Standard TherapySymptomatic Colorectal CancerMedDRA version: 18.1Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-000550-12-BGXBiotech Germany GmbH335
Active, not recruiting
Phase 1
A Study Evaluating Xilonix™ in Symptomatic Colorectal Cancer Patients Refractory To Standard TherapySymptomatic Colorectal CancerMedDRA version: 18.0Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-000550-12-CZXBiotech Germany GmbH276
Active, not recruiting
Phase 1
A Study Evaluating Xilonix™ in Symptomatic Colorectal Cancer Patients Refractory To Standard TherapySymptomatic Colorectal CancerMedDRA version: 19.1Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-000550-12-PLXBiotech Germany GmbH335
A Study to Determine if Caffeine... | Clinical Trial